Defining the role of baclofen for the treatment of alcohol dependence: A systematic review of the evidence

CNS Drugs

Volumn 26, Issue 1, 2012, Pages 69-78

  Muzyk, Andrew J ^a,b   Rivelli, Sarah K ^b   Gagliardi, Jane P ^b  

^a Campbell University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholism; Baclofen; GABA B receptor agonists

Indexed keywords

ACAMPROSATE; AMITRIPTYLINE; BACLOFEN; DIAZEPAM; NALTREXONE; PLACEBO; TOPIRAMATE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; DEPRESSION; DIZZINESS; DRINKING BEHAVIOR; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANIMALS; BACLOFEN; EVIDENCE-BASED MEDICINE; GABA-B RECEPTOR AGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 83455178817     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11597320-000000000-00000     Document Type: Review

References (48)

1. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorder. Lancet 2009; 373: 2223-33
2. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States. Arch Gen Psychiatry 2007; 64: 830-42
3. Rehm J, Baliunas D, Guilherme B, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 2010; 105: 817-43
4. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and metaanalysis. Drug Alcohol Rev 2010; 29: 437-45
5. Swift R. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm 2007; 64 (5 Suppl. 3): S12-22 (Pubitemid 46339256)
6. Mann K. Pharmacotherapy of alcohol dependence: a review of clinical data. CNS Drugs 2004; 18: 485-504 (Pubitemid 38829945)
7. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318-25 (Pubitemid 29174484)
8. Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9): CD004332
9. Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12: CD001867
10. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. JAMA 2006; 295: 2003-17 (Pubitemid 44794003)
11. Baltieri DA, Daro FR, Ribeiro PL, et al. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103: 2035-44
12. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-51 (Pubitemid 47606653)
13. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004; 61: 905-12 (Pubitemid 39181080)
14. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677-85 (Pubitemid 36577440)
15. Caputo F, Addolorato G, Stoppo M, et al. Comparing and combining gamma-hydroxybutric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study. Eur Neuropsychopharmacol 2007; 17: 781-9 (Pubitemid 47588865)
16. Caputo F, Addolorato G, Lorenzini F, et al. Gammahydroxybutric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend 2003; 71: 85-91 (Pubitemid 36385156)
17. Gallimberti L, Ferri M, Ferrara SD, et al. Gammahydroxybutric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992; 16: 673-6
18. Addolorato G, Caputo F, Capristo E, et al. Ability of baclofen in reducing alcohol craving and intake: II. Preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 67-71 (Pubitemid 30062783)
19. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 2004; 28: 1517-23 (Pubitemid 39390473)
20. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-8
21. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007; 370: 1915-22 (Pubitemid 350192657)
22. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 1-9
23. AddoloratoG, Leggio L, FerrulliA, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011; 46: 312-7
24. Colombo G, Addolorato G, Agabio R, et al. Role of GABAB receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004; 6: 403-14
25. AddoloratoG, Leggio L, Cardone S, et al. Role of theGABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol 2009; 43: 559-63
26. Krystal JH, Tabakoff B. Ethanol abuse, dependence, and withdrawal: neurobiology and clinical implications. In: Davis KL, Charney D, Coyle JT, et al., editors. Neuropsychopharmacology: 5th generation of progress. New York (NY): LippincottWilliams and Wilkins; 2002: 1425-43
27. Sinha R, Fox HC, Hong KA, et al. Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology 2009; 34: 1198-208
28. Sinha R, Li CS. Imaging stress-and cue-inducing and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev 2007; 26: 25-31
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
30. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 1-12 (Pubitemid 26120810)
31. Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 2006; 2: 80-9 (Pubitemid 44284090)
32. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using highdose baclofen: a self-case report of a physician. Alcohol Alcohol 2005; 40: 147-50 (Pubitemid 40347343)
33. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 2007; 42: 158-60 (Pubitemid 47072109)
34. Agabio R, Marras P, Addolorato G, et al. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J Clin Psychopharm 2007; 27: 319-20 (Pubitemid 46763329)
35. Gerkin R, Curry SC, Vance MV, et al. First-order elimination kinetics following baclofen overdose. Ann Emerg Med 1986; 15: 843-6 (Pubitemid 16071154)
36. VanDierendonk DR, Dire DJ. Baclofen and ethanol ingestion: a case report. J Emerg Med 1999; 17: 989-93 (Pubitemid 29528070)
37. Chen KS, Bullard MJ, Chien YY, et al. Baclofen toxicity in patients with severely impaired renal function. Ann Pharmacother 1997; 31: 1315-20 (Pubitemid 27498019)
38. Vivitrol-[package insert]. Waltharn (MA): Alkermes, Inc., 2010
39. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010; 16: 4905-12
40. Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 2009; 33: 19-30
41. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010; 16: 2113-7
42. Krupitsky EM, Burakov AM, Ivanov VB, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend 1993; 33: 157-63 (Pubitemid 23286634)
43. Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumptions in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009; 103: 30-6
44. Karilla L, Gorelick D, Weinstein A, et al. New treatment for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008; 11: 425-38 (Pubitemid 351482505)
45. Keena GA, Nielsen DM, Mello P, et al. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 2007; 21: 213-37 (Pubitemid 46425628)
46. Heinzerlin KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 177-84 (Pubitemid 44666282)
47. Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 2008; 20: 145-55 (Pubitemid 352009285)
48. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Apr 25]